Navigation Links
Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis

n 0in 0pt; TEXT-ALIGN: justify">Chi-Med has a further botanical candidate, HMPL-002, a radio-sensitizer for head and neck and non-small cell lung cancer, which is in Phase I/II in the US and in proof-of-concept study in China. Chi-Med’s further pre-clinical drug development pipeline is focused on oncology and auto-immune indications. These compounds include synthetic and semi-synthetic single chemical entities in addition to botanical and natural product candidates.

At the meeting of Hutchison MediPharma’s Scientific Advisory Board held in Shanghai, China in late-June 2007, the Board, which includes key opinion leaders in the inflammatory bowel disease area, such as Dr. William J. Sandborn, Professor of Medicine at the Mayo Clinic College of Medicine, Vice Chair of the Division of Gastroenterology and Hepatology, and Director of the Inflammatory Bowel Disease Interest Group of the Mayo Clinic and Dr. Stephan Targan, Director of both the Inflammatory Bowel Disease Center and Division of Gastroenterology at Cedars-Sinai Medical Center, Los Angeles expressed high enthusiasm over HMPL-004.

Dr. Stephan Targan commented:

“HMPL-004 has a different mechanism of action. Based on the promising results from this study, HMPL-004 is warranted for further clinical studies to fully evaluate its efficacy and safety profile for the treatment of Ulcerative Colitis.”

Dr. Samantha Du, Chief Scientific Officer of Chi-Med and Managing Director of Hutchison MediPharma said:






Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/31/2014)... 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... for the quarter ended June 30, 2014. Financial ... 2014 Revenue Total revenue for the quarter ended June ... the quarter ended June 30, 2013 primarily due to IMBRUVICA ... Total revenue for the six months ended June ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif. , July 31, 2014 ... ) today provided an update on its pipeline ... of 2014, Alexza expects to initiate a Phase ... which is being developed for the management of ... identified two new Staccato -based product candidates ...
(Date:7/31/2014)... 31, 2014 Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... initiated the development of its lead molecule, Anatabine Citrate, ... has selected Quotient Clinical, The Translational Pharmaceutics Company, based ... to run its early development programs. The ... by the end of the third quarter with the ...
Breaking Medicine Technology:Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4
... 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced,follow-up ... of GVAX immunotherapy,for pancreatic cancer which was ... Center. The trial enrolled 60 patients with,operable ... of their tumor and adjuvant radiation and,chemotherapy. ...
... 2002 , CHICAGO/DARMSTADT, Germany, June 4, 2007 – ... the American Society of,Clinical Oncology (ASCO) annual meeting ... patients with newly diagnosed,glioblastoma – a particularly aggressive ... integrin inhibitor targeting the,tumor and its vasculature. , ...
Cached Medicine Technology:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 2Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 3Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 4Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of,GVAX Immunotherapy for Pancreatic Cancer 5Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5
(Date:7/31/2014)... Flagstaff, AZ (PRWEB) July 31, 2014 ... long-term substance abuse treatment program in Flagstaff, AZ, learn ... an understanding of equipment and paddle strokes in preparation ... Juan River. , "I think that [the kayaking course] ... things that they struggle with in their early part ...
(Date:7/31/2014)... CA (PRWEB) July 31, 2014 Dr. ... closure in front of an enthusiastic audience of international ... Trichophytic Closure improves the appearance of a patient’s ... results of this procedure are minimally detectable in most ... technique improves on the original method of donor wound ...
(Date:7/31/2014)... July 31, 2014 Located on one of ... Macy’s, The Rothenberg Law Firm LLP has moved its office ... , The Rothenberg Law Firm has been handling catastrophic personal ... spurred by growth in the firm’s continued success in seeking ... New York office has a team of experienced and successful ...
(Date:7/31/2014)... To further educate the public, The Rothenberg Law ... information regarding leaving children in hot vehicles: , Leaving ... Because a child’s body can heat up three to ... alone in a hot vehicle puts them at extreme ... of Children Left Alone in a Car , According ...
(Date:7/31/2014)... Village, IL (PRWEB) July 31, 2014 ... solutions, today announced a new sponsorship of the ... and center are Etymotic’s hearing protection products ETY•Plugs® ... while protecting against the harmful effects of high-level ... off the sponsorship at the Drum Corps International ...
Breaking Medicine News(10 mins):Health News:Back2Basics Substance Abuse Residents Take Kayaking Class for the First Time 2Health News:Novel Technique in Wound Closure Delivers More Discreet Results in Hair Transplant Patients 2Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 2Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 3Health News:Etymotic Research Becomes The Official Hearing Protection Sponsor Of DrumLine Battle 2
... drinks is associated with binge drinking, alcohol-related social problems ... researchers at the University at Buffalo,s Research Institute on ... Journal of Caffeine Research this spring, UB ... examined substance use by 226 Western New York ...
... , MONDAY, June 20 (HealthDay News) -- Nearly 6 million ... allergic to at least one food, with peanuts, milk and shellfish ... finds. Researchers conducted a nationally representative survey of the parents ... child who had a food allergy. Of those, about 30 percent ...
... -- Cardiac arrest victims are more likely to survive if ... using a defibrillator to deliver an electric shock to the ... of 815 American and Canadian patients who suffered sudden cardiac ... using either an automated external defibrillator or a manual defibrillator. ...
... , MONDAY, June 20 (HealthDay News) -- For gay ... on the support of the local community, a new study ... who reveal their sexual orientation typically boost their self-esteem and ... that disclosing one,s sexual identity makes people even happier than ...
... low-calorie potato chips and other foods could backfire and ... study published by the American Psychological Association. The ... wisdom that foods made with fat substitutes help with ... interfere with the body,s ability to regulate food intake, ...
... The overall risk of injury and concussion among young ice ... they,re first allowed to bodycheck, according to a new study. ... Alberta, which allowsbodychecking at the Pee Wee level (ages 11 ... Bantam level (ages 13 to 14). The study included ...
Cached Medicine News:Health News:Energy drinks linked to substance use in musicians, study shows 2Health News:Energy drinks linked to substance use in musicians, study shows 3Health News:One in 12 U.S. Children May Have Food Allergies: Report 2Health News:One in 12 U.S. Children May Have Food Allergies: Report 3Health News:Faster Transition From CPR to Defibrillator May Save Lives 2Health News:Support Is Key to 'Coming Out' Process for Gay People: Study 2Health News:Fat substitutes linked to weight gain 2Health News:Results of Bodychecking in Youth Hockey Examined 2
eValuator fixed-curve diagnostic electrophysiology catheters offer an effective balance between clinical performance and cost....
Wire mesh braided design with a platinum core....
... The St. Jude Medical® Pacing System Analyzer ... solution for implantation testing, programming and interrogation ... as an easy-to-use accessory to the St. ... testing by obtaining measurements of intrinsic P- ...
... The Libert Coronary Stent ... generation of lesion access ... flexibility, a low crossing ... delivery catheter, the performance ...
Medicine Products: